CONCEPT

Corporate Mortality Curve

The empirical finding — as regular as biological mortality — that half of all publicly traded companies disappear within ten years, following a curve mathematically indistinguishable from the death curve of organisms.

West's research, conducted with colleagues at the Santa Fe Institute using data on over 23,000 publicly traded American companies from 1950 through the early 2010s, reveals a regularity so clean it is almost eerie. The probability that a publicly traded company will die in a given year is roughly independent of its age and size. The survival curve — the fraction of companies surviving to a given age — declines in a pattern mathematically indistinguishable from the mortality curve of biological organisms. Half of all publicly traded companies are gone within approximately ten years. By thirty years, roughly ninety percent have disappeared — absorbed, acquired, bankrupt, or dissolved. The mortality rate has remained stable for over sixty years. It does not vary significantly between industries. It does not respond to business cycles in any lasting way. The mortality is structural, not circumstantial — a consequence of the hierarchical network topology that all mature corporations converge toward.

In the AI Story

Hedcut illustration for Corporate Mortality Curve — Corporate Mortality Curve

The quantitative regularity of the corporate mortality curve is one of the most counterintuitive findings in business research. Economists typically model firm survival as a function of competitive dynamics, management quality, product-market fit, and macroeconomic conditions. West's data suggests something quite different: firm survival is a structural property of the organizational network itself, essentially independent of the specific strategies the firm pursues.

The biological parallel is not decorative. West argues it arises from the same underlying cause: hierarchical branching networks optimized for efficient distribution of resources. As a company grows, its organizational chart becomes, topologically, a fractal tree — CEO at the trunk, divisions branching into departments, departments into teams, teams into individual contributors. The network is optimized for efficient delivery of directives and aggregation of results. It is also, by its structure, hostile to novelty. The same geometry produces the same mathematical consequence: a mortality curve mathematically indistinguishable from that of biological organisms.

The regularity is remarkable across multiple dimensions. The curve does not depend on founding date — companies born in the 1950s die at the same rate as companies born in the 2000s. It does not depend on industry — technology companies, manufacturing companies, and retailers all follow similar trajectories. It does not depend on size at maturity — once a company has grown past early startup phase, the mortality dynamics are remarkably uniform.

The Software Death Cross that Edo Segal describes in The Orange Pill represents, in West's framework, the empirical manifestation of metabolic acceleration against an unchanged network. SaaS companies that adopted AI without restructuring their hierarchies experienced predictable consequences: their mortality curve steepened rather than extended.

The single variable that West's research identifies as potentially shifting the mortality curve is network topology itself. Companies that periodically reinvent themselves — undergoing structural transformations radical enough to reset their growth dynamics — can extend their lifespans. But the transformations are rare, painful, and typically driven by existential crisis rather than strategic choice. AI may be the first technology powerful enough to make such restructuring deliberate rather than accidental — if organizations choose to allow it.

Origin

The corporate mortality analysis was conducted by Madeleine Daepp, Marcus Hamilton, Geoffrey West, and Luis Bettencourt, published in 2015 in the Journal of the Royal Society Interface as 'The mortality of companies.' The paper established the stability and universality of the corporate survival curve across multiple decades and industries.

Key Ideas

Half dead within ten years. The median lifespan of publicly traded American firms is approximately a decade — a finding stable across six decades of data.

Age-independent mortality. The probability of death in any given year does not strongly depend on the company's current age, once past early startup phase.

Biologically shaped curve. The survival curve is mathematically indistinguishable from the mortality curve of biological organisms.

Industry-independent. The pattern holds across technology, manufacturing, retail, finance — the structural dynamics transcend sector-specific factors.

Topology-dependent exception. The rare companies that extend their lifespans substantially do so by restructuring their organizational networks, not by optimizing within existing structures.

Debates & Critiques

Some management scholars have argued that West's biological analogy overstates the determinism of the mortality curve. Critics note that specific companies — IBM, General Electric, Procter & Gamble — have survived for over a century, suggesting that management quality and strategic adaptation matter more than the framework allows. West responds that these exceptions prove the rule: they survived because they underwent radical network restructuring at multiple points, not because they optimized within a fixed architecture.

Appears in the Orange Pill Cycle

Geoffrey West — On AI